A1ZN34 logo

AstraZeneca BOVESPA:A1ZN34 Stock Report

Last Price

R$69.41

Market Cap

R$1.3t

7D

0.4%

1Y

35.5%

Updated

07 Feb, 2025

Data

Company Financials +

A1ZN34 Stock Overview

A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. More details

A1ZN34 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance3/6
Financial Health3/6
Dividends3/6

My Notes

Capture your thoughts, links and company narrative

AstraZeneca PLC Competitors

Price History & Performance

Summary of share price highs, lows and changes for AstraZeneca
Historical stock prices
Current Share PriceUK£69.41
52 Week HighUK£82.80
52 Week LowUK£50.80
Beta0.20
1 Month Change2.13%
3 Month Change11.41%
1 Year Change35.54%
3 Year Changen/a
5 Year Changen/a
Change since IPO32.64%

Recent News & Updates

Recent updates

Shareholder Returns

A1ZN34BR PharmaceuticalsBR Market
7D0.4%1.0%-1.3%
1Y35.5%-18.3%-8.3%

Return vs Industry: A1ZN34 exceeded the BR Pharmaceuticals industry which returned -17.3% over the past year.

Return vs Market: A1ZN34 exceeded the BR Market which returned -7.3% over the past year.

Price Volatility

Is A1ZN34's price volatile compared to industry and market?
A1ZN34 volatility
A1ZN34 Average Weekly Movement4.2%
Pharmaceuticals Industry Average Movement5.9%
Market Average Movement5.4%
10% most volatile stocks in BR Market9.6%
10% least volatile stocks in BR Market3.2%

Stable Share Price: A1ZN34 has not had significant price volatility in the past 3 months compared to the BR market.

Volatility Over Time: A1ZN34's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199289,900Pascal Soriotwww.astrazeneca.com

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease.

AstraZeneca PLC Fundamentals Summary

How do AstraZeneca's earnings and revenue compare to its market cap?
A1ZN34 fundamental statistics
Market capR$1.30t
Earnings (TTM)R$40.87b
Revenue (TTM)R$314.12b

31.7x

P/E Ratio

4.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A1ZN34 income statement (TTM)
RevenueUS$54.07b
Cost of RevenueUS$9.64b
Gross ProfitUS$44.44b
Other ExpensesUS$37.40b
EarningsUS$7.04b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Apr 29, 2025

Earnings per share (EPS)4.54
Gross Margin82.18%
Net Profit Margin13.01%
Debt/Equity Ratio71.0%

How did A1ZN34 perform over the long term?

See historical performance and comparison

Dividends

2.0%

Current Dividend Yield

68%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 12:21
End of Day Share Price 2025/02/07 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AstraZeneca PLC is covered by 76 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Kamla SinghAlphaValue
John EadeArgus Research Company